TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11314239
Drug: Clodronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (100 mg i.m./14 days)
Study: 11314239
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid treatment (fluticasone or beclomethasone) without clodronate
Study: 8070823
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/day plus aspirin and calcium blockers
Study: 8070823
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (aspirin and calcium blockers)
Study: 3554456
Drug: TMP-SMZ (oral)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ (oral)
Study: 3554456
Drug: TMP-SMZ (intravenous)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ (intravenous)
Study: 3554456
Drug: TMP-SMZ in
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ in combination with aminoglycoside or antipseudomonal penicillin
Study: 30918100
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (DMF) treatment
Study: 26492541
Drug: CIO (Complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIO (Complete Insulin Orders)
Study: 22865311
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) in smokers with short time to treatment (<3 hours)
Study: 22865311
Drug: Fibrinolysis in
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrinolysis in smokers with short time to treatment (<3 hours)
Study: 22865311
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) in non-smokers with short time to treatment (<3 hours)
Study: 22865311
Drug: Fibrinolysis in
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrinolysis in non-smokers with short time to treatment (<3 hours)
Study: 22865311
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) in patients with >3 hours to treatment
Study: 22865311
Drug: Fibrinolysis in
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrinolysis in patients with >3 hours to treatment
Study: 15868655
Drug: D-003 5
Normalized name: 5-HYDROXYTRYPTOPHAN, D-
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 5 mg/day
Study: 15868655
Drug: D-003 10
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 10 mg/day
Study: 11253161
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg/day
Study: 12534315
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg/day
Study: 8929439
Drug: Phentolamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (1 mg/kg IV over 20 min)
Study: 21123458
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg choline/d
Study: 25160013
Drug: GTE2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTE2 (2 g/d)
Study: 25160013
Drug: GTE4 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTE4 (4 g/d)
Study: 25160013
Drug: GTE6 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTE6 (6 g/d)
Study: 17261427
Drug: Over-the-counter medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter medications
Study: 17261427
Drug: Drug-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problems
Study: 15517847
Drug: Intramuscular ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ziprasidone
Study: 11477858
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection combined with chemotherapy (Group A)
Study: 11477858
Drug: Chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Group C)
Study: 11477858
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (Group B)
Study: 8588267
Drug: Flavoxate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoxate treatment (1,200 mg/day, 400 mg t.i.d. for 12 weeks)
Study: 2523634
Drug: Chronic enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic enoximone therapy (1 and 2 mg/kg)
Study: 31415883
Drug: Salmonella typhoid
Normalized name: Typhoid vaccine (salmonella typhi Ty21a)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella typhoid vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur)
Study: 26183021
Drug: TBCT (Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBCT (Traditional Behavioral Couple Therapy)
Study: 26183021
Drug: IBCT (Integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBCT (Integrative Behavioral Couple Therapy)
Study: 20642246
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 50 or 100 mg
Study: 24353022
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR 5 or 10 mg
Study: 16801461
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy alone (Control)
Study: 11094583
Drug: oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral clonidine 2 micrograms kg‐1
Study: 11094583
Drug: oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral clonidine 4 micrograms kg‐1
Study: 1473445
Drug: Cholesterol-lowering drug,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering drug, simvastatin
Study: 6628810
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) at three dose levels
Study: 31680600
Drug: Subanesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic ketamine infusion
Study: 29642312
Drug: Maltitol oral
Normalized name: Maltitol
DrugBank: Maltitol (DB16867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol oral spray
Study: 25876529
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (DSM 17938) at a dose of 10^8 colony forming units
Study: 25876529
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical formulation without live micro-organisms)
Study: 20162373
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), average of ten sessions
Study: 19597054
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake of 5 to 14.9 g/d
Study: 15878442
Drug: telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telithromycin 800 mg qd for 7-10 days
Study: 10102956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg curcumin
Study: 12495265
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg curcumin
Study: 12495265
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg curcumin
Study: 9802626
Drug: Amoxicillin/clavulanate or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate or erythromycin for 10 days (control)
Study: 7706609
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (150 mg/day for 1 week, followed by 300 mg/day for 3 weeks)
Study: 2615456
Drug: Yi‐qi Huo‐xue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yi‐qi Huo‐xue Injection (YHI)
Study: 27699890
Drug: Megagen AnyRidge
Normalized name: benzalkonium chloride Topical Cream [Abridge Cold Sore]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megagen AnyRidge (AR) implant
Study: 27699890
Drug: Megagen EZ
Normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megagen EZ Plus Internal (EZ) implant
Study: 18848434
Drug: Standardized capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized capsule of Camellia sinensis (CSC)
Study: 15723941
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injections (4-mg/mL solution, 0.5 mL, once per week for 4 weeks)
Study: 15723941
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride (saline) solution (0.5 mL, once per week for 4 weeks)
Study: 11880081
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of 1% lidocaine in the lateral and apical periprostatic regions, 5 mL in each point, 10 minutes before the biopsy
Study: 11880081
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lidocaine injection)
Study: 12063831
Drug: Preoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy
Study: 9667276
Drug: Both preoperative
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preoperative and postoperative therapy
Study: 9667276
Drug: Modern radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern radiation treatment techniques
Study: 22228322
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for moderate to severe hot flushes
Study: 15711601
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy protein/high-calcium diet (DP, 2400 mg Ca/d)
Study: 15711601
Drug: High mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mixed protein/moderate calcium diet (MP, 500 mg Ca/d)
Study: 11801552
Drug: Topical DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical DFMO
Study: 10422932
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg with fentanyl 25 microg
Study: 10422932
Drug: Bupivacaine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.25 mg with fentanyl 25 microg
Study: 7768495
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin day-1 for 3 weeks
Study: 733132
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin and tetracycline
Study: 733132
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin and intramuscular tobramycin
Study: 29462657
Drug: Serlopitant 5
Normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serlopitant 5 mg
Study: 31523039
Drug: Dexamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12 mg, two intramuscular injections, 24 hours apart)
Study: 31523039
Drug: Betamethasone (11.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (11.4 mg, two intramuscular injections, 24 hours apart)
Study: 19192350
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (0.25 mg per day) during endometrial priming with oestradiol (group I, n = 49)
Study: 19192350
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group II, n = 49) receiving only endometrial preparation
Study: 15235686
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for 24 months
Study: 3034018
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg once daily
Study: 9291556
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including counselling and occlusal adjustment)
Study: 9291556
Drug: Demand for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand for rescue treatment
Study: 25893562
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CR) supplementation at 20 g day(‐1) during cast-immobilization
Study: 23911535
Drug: Basal Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Bolus regimen with glargine once daily and glulisine before meals
Study: 23911535
Drug: Basal Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Plus regimen with glargine once daily and supplemental doses of glulisine before meals
Study: 23911535
Drug: Medicine patients
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine patients
Study: 18422590
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 35 mg once weekly
Study: 18422590
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) 20 microg once daily
Study: 14976882
Drug: Large dosage
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dosage of Salvia injection (24 ml)
Study: 14976882
Drug: Middle dosage
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dosage of Salvia injection (16 ml)
Study: 14976882
Drug: Small dosage
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dosage of Salvia injection (8 ml)
Study: 14976882
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Salvia injection)
Study: 8835705
Drug: Brofaromine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (150 mg daily)
Study: 3609849
Drug: D5NS infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D5NS infusion (Control)
Study: 25007166
Drug: Heparin-grafted dialyzer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-grafted dialyzer
Study: 20235450
Drug: Diplopore puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diplopore puncture of tympanum and intratympanic administration (DPTIA) combined with medication
Study: 20235450
Drug: Haplopore puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplopore puncture of tympanum combined with medication
Study: 18672766
Drug: Modified Wuhua
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Wuhua Decoction (WHD) plus oral levocetirizine tablet
Study: 18672766
Drug: Levocetirizine tablet
Normalized name: levocetirizine Oral Tablet
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine tablet alone
Study: 16096356
Drug: Female workers
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female workers in public administration
Study: 9372530
Drug: quetiapine (300-700
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine (300-700 mg/day)
Study: 9372530
Drug: clozapine (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: clozapine (300-600 mg/day)
Study: 9372530
Drug: haloperidol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (10-20 mg/day)
Study: 9382121
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg alendronate
Study: 12006327
Drug: Alendronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (all doses)
Study: 24997476
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 25‐30 minutes of aerobic exercise (STAN)
Study: 24997476
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50‐60 minutes of aerobic exercise (HIGH)
Study: 24997476
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50‐60 minutes of combined aerobic and resistance exercise (COMB)
Study: 20350745
Drug: Foot gel
Normalized name: CLOTRIMAZOLE 0.01 kg in 1 kg TOPICAL GEL [Forticept Antifungal Foot Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot gel pads
Study: 20350745
Drug: No foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: No foot gel pads
Study: 18669993
Drug: Individual Placement
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Placement and Support (IPS) + Treatment as Usual (TAU)
Study: 14639098
Drug: Adenosine injection
Normalized name: adenosine Injection
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine injection (doses not specified)
Study: 6507184
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg)
Study: 10888041
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with 6 mg/m2 of cisplatin and split-course radiotherapy (Group 2)
Study: 10888041
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with two cycles of etoposide, ifosfamide, and cisplatin followed by split-course radiotherapy (Group 3)
Study: 20011881
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 24 g in 250 ml saline solution
Study: 20011881
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml saline solution)
Study: 11604268
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid added to enteric-coated matrix granules and tablet matrix
Study: 9819787
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (Premarin) 0.625 mg/day orally plus medroxyprogesterone acetate (Farlutal) 10 mg/day orally (RHRT group)
Study: 9819787
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (NRHRT group)
Study: 7650533
Drug: Total lifetime
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total lifetime dose of ethanol
Study: 2523660
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral isradipine
Study: 2523660
Drug: Isradipine treatment
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine treatment over 12 weeks
Study: 848803
Drug: Ragweed inhalation
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed inhalation challenge
Study: 31808584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LLLT and fluoride varnish (L + FV)
Study: 16830018
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% premixed with 40 mg of lidocaine
Study: 16830018
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% given 60 seconds after 40 mg of lidocaine
Study: 16830018
Drug: Venous occlusion
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous occlusion for 60 seconds with lidocaine 1% (40 mg) followed by propofol
Study: 7901024
Drug: Fenspiride hydrochloride
Normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride hydrochloride (80 mg) administered IV
Study: 7901024
Drug: Fenspiride hydrochloride
Normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride hydrochloride (80 mg) administered orally
Study: 7901024
Drug: Fenspiride hydrochloride
Normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride hydrochloride (IV and oral)
Study: 26895001
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine without liposuction at a dosage of 28 mg/kg
Study: 26895001
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine with liposuction at a dosage of 45 mg/kg
Study: 1095122
Drug: L-Dopa
Normalized name: L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-Dopa
Study: 19014156
Drug: Flapless immediately
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless immediately loaded implants
Study: 19014156
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants (submerged or unsubmerged)
Study: 12683470
Drug: Nefazodone (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (300-600 mg per day in two divided doses)
Study: 19217168
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nefazodone and psychotherapy
Study: 12683470
Drug: Nefazodone (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (alone or in combination with CBASP)
Study: 7560617
Drug: Captopril therapy
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril therapy